BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematology/Oncology Clinics of North America 2002;16:37-52. [DOI: 10.1016/s0889-8588(01)00007-7] [Cited by in Crossref: 102] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Itoi T, Sugimoto M, Umeda J, Sofuni A, Tsuchiya T, Tsuji S, Tanaka R, Tonozuka R, Honjo M, Moriyasu F, Kasuya K, Nagakawa Y, Abe Y, Takano K, Kawachi S, Shimazu M, Soga T, Tomita M, Sunamura M. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. Int J Mol Sci 2017;18:E767. [PMID: 28375170 DOI: 10.3390/ijms18040767] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
2 Karakhanova S, Link J, Heinrich M, Shevchenko I, Yang Y, Hassenpflug M, Bunge H, von Ahn K, Brecht R, Mathes A, Maier C, Umansky V, Werner J, Bazhin AV. Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology. 2015;4:e998519. [PMID: 26137414 DOI: 10.1080/2162402x.2014.998519] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 8.2] [Reference Citation Analysis]
3 Kusama K, Okamoto Y, Saito K, Kasahara T, Murata T, Ueno Y, Kobayashi Y, Kamada Y, Miyoshi E. Reevaluation of Pholiota squarrosa lectin-reactive haptoglobin as a pancreatic cancer biomarker using an improved ELISA system. Glycoconj J 2017;34:537-44. [PMID: 28455724 DOI: 10.1007/s10719-017-9772-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Shi XH, Li X, Zhang H, He RZ, Zhao Y, Zhou M, Pan ST, Zhao CL, Feng YC, Wang M, Guo XJ, Qin RY. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Sci Rep 2018;8:7638. [PMID: 29769534 DOI: 10.1038/s41598-018-22493-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
5 Corbo V, Tortora G, Scarpa A. Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets. 2012;13:744-752. [PMID: 22458520 DOI: 10.2174/138945012800564103] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
6 Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Ziogas A, Anton-Culver H, Brentnall TA. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res. 2011;10:2359-2376. [PMID: 21443201 DOI: 10.1021/pr101148r] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
7 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
8 Paulo JA, Lee LS, Wu B, Banks PA, Steen H, Conwell DL. Mass spectrometry-based proteomics of endoscopically collected pancreatic fluid in chronic pancreatitis research. Proteomics Clin Appl. 2011;5:109-120. [PMID: 21360826 DOI: 10.1002/prca.201000098] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
9 Tian R, Wei LM, Qin RY, Li Y, Du ZY, Xia W, Shi CJ, Jin H. Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins. Dig Dis Sci 2008;53:65-72. [PMID: 17492507 DOI: 10.1007/s10620-007-9823-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
10 Xie G, Lu L, Qiu Y, Ni Q, Zhang W, Gao YT, Risch HA, Yu H, Jia W. Plasma metabolite biomarkers for the detection of pancreatic cancer. J Proteome Res 2015;14:1195-202. [PMID: 25429707 DOI: 10.1021/pr501135f] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
11 Mechref Y, Hu Y, Garcia A, Hussein A. Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis 2012;33:1755-67. [PMID: 22740464 DOI: 10.1002/elps.201100715] [Cited by in Crossref: 109] [Cited by in F6Publishing: 92] [Article Influence: 12.1] [Reference Citation Analysis]
12 Cheng RF, Wang J, Zhang JY, Sun L, Zhao YR, Qiu ZQ, Sun BC, Sun Y. MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression. Chin J Cancer 2016;35:64. [PMID: 27371108 DOI: 10.1186/s40880-016-0128-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma. Med Oncol. 2013;30:583. [PMID: 23609192 DOI: 10.1007/s12032-013-0583-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
14 Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW, Zhao Y. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2013;139:1117-1127. [PMID: 23546595 DOI: 10.1007/s00432-013-1422-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
15 Rodriguez JA, Li M, Yao Q, Chen C, Fisher WE. Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J Surg. 2005;29:297-305. [PMID: 15696394 DOI: 10.1007/s00268-004-7843-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
16 Vareed SK, Bhat VB, Thompson C, Vasu VT, Fermin D, Choi H, Creighton CJ, Gayatri S, Lan L, Putluri N, Thangjam GS, Kaur P, Shabahang M, Giri JG, Nesvizhskii AI, Asea AA, Cashikar AG, Rao A, McLoughlin J, Sreekumar A. Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma. PLoS One 2011;6:e17177. [PMID: 21448452 DOI: 10.1371/journal.pone.0017177] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
17 Zhou Y, Huang J, Yu X, Jiang X, Shi Y, Weng Y, Kuai Y, Lei L, Ren G, Feng X, Zhong G, Liu Q, Pan H, Zhang X, Zhou R, Lu C. LITAF is a potential tumor suppressor in pancreatic cancer. Oncotarget 2018;9:3131-42. [PMID: 29423035 DOI: 10.18632/oncotarget.23220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Lin Z, Simeone DM, Anderson MA, Brand RE, Xie X, Shedden KA, Ruffin MT, Lubman DM. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res 2011;10:2602-11. [PMID: 21417406 DOI: 10.1021/pr200102h] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
19 Peng W, Zhao J, Dong X, Banazadeh A, Huang Y, Hussien A, Mechref Y. Clinical application of quantitative glycomics. Expert Rev Proteomics 2018;15:1007-31. [PMID: 30380947 DOI: 10.1080/14789450.2018.1543594] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
20 Liu MP, Guo XZ, Xu JH, Wang D, Li HY, Cui ZM, Zhao JJ, Ren LN. New tumor-associated antigen SC6 in pancreatic cancer. World J Gastroenterol 2005;11:7671-5. [PMID: 16437697 DOI: 10.3748/wjg.v11.i48.7671] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Bazhin AV, Bayry J, Umansky V, Werner J, Karakhanova S. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Oncoimmunology 2013;2:e25736. [PMID: 24327934 DOI: 10.4161/onci.25736] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
22 Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33:799-807. [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
23 Fry LC, Mönkemüller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393:883-890. [PMID: 18266003 DOI: 10.1007/s00423-007-0276-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
24 Yan Q, Hu D, Li M, Chen Y, Wu X, Ye Q, Wang Z, He L, Zhu J. The Serum MicroRNA Signatures for Pancreatic Cancer Detection and Operability Evaluation. Front Bioeng Biotechnol. 2020;8:379. [PMID: 32411694 DOI: 10.3389/fbioe.2020.00379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
25 Hernandez YG, Lucas AL. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol 2016;8:18-29. [PMID: 26798434 DOI: 10.4251/wjgo.v8.i1.18] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
26 Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, Kuhajda F. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18:2380-2385. [PMID: 19723916 DOI: 10.1158/1055-9965.epi-09-0144] [Cited by in Crossref: 60] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
27 Yu KH, Barry CG, Austin D, Busch CM, Sangar V, Rustgi AK, Blair IA. Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res 2009;8:1565-76. [PMID: 19199705 DOI: 10.1021/pr800904z] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
28 Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K, Nakamura Y, Yamao K. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol. 2010;45:52-59. [PMID: 19789838 DOI: 10.1007/s00535-009-0114-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
29 Li C, Kim HY, Vuong H, Patwa T, Pal M, Brand RE, Simeone DM, Lubman DM. The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line. Cancer Biomark. 2010;7:25-37. [PMID: 21045262 DOI: 10.3233/cbm-2010-0145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
30 Beaty RM, Gronborg M, Pollack JR, Maitra A. Target discovery and validation in pancreatic cancer. Methods Mol Biol 2007;360:57-89. [PMID: 17172725 DOI: 10.1385/1-59745-165-7:57] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Soltek S, Karakhanova S, Golovastova M, D'Haese JG, Serba S, Nachtigall I, Philippov PP, Werner J, Bazhin AV. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. Naunyn Schmiedebergs Arch Pharmacol 2015;388:1121-8. [PMID: 26105003 DOI: 10.1007/s00210-015-1147-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Wang X, Wang J, Chen F, Zhong Z, Qi L. Detection of K-ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study. Exp Ther Med 2018;15:527-31. [PMID: 29250161 DOI: 10.3892/etm.2017.5368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
33 Yang J, Li J, Zhu R, Zhang H, Zheng Y, Dai W, Wang F, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Wang J, Xia Y, Lu J, Zhou Y, Guo C. K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysis. Dis Markers 2014;2014:573783. [PMID: 25301978 DOI: 10.1155/2014/573783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
34 Cheung W, Darfler MM, Alvarez H, Hood BL, Conrads TP, Habbe N, Krizman DB, Mollenhauer J, Feldmann G, Maitra A. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 2008;8:608-16. [PMID: 18849643 DOI: 10.1159/000161012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
35 Shin EJ, Canto MI. Pancreatic cancer screening. Gastroenterol Clin North Am. 2012;41:143-157. [PMID: 22341255 DOI: 10.1016/j.gtc.2011.12.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
36 Wu L, Huang P, Wang F, Li D, Xie E, Zhang Y, Pan S. Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer. Ann Transl Med 2015;3:328. [PMID: 26734638 DOI: 10.3978/j.issn.2305-5839.2015.11.17] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
37 Asai Y, Itoi T, Sugimoto M, Sofuni A, Tsuchiya T, Tanaka R, Tonozuka R, Honjo M, Mukai S, Fujita M, Yamamoto K, Matsunami Y, Kurosawa T, Nagakawa Y, Kaneko M, Ota S, Kawachi S, Shimazu M, Soga T, Tomita M, Sunamura M. Elevated Polyamines in Saliva of Pancreatic Cancer. Cancers (Basel). 2018;10. [PMID: 29401744 DOI: 10.3390/cancers10020043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
38 Moutinho-Ribeiro P, Macedo G, Melo SA. Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? Front Endocrinol (Lausanne) 2018;9:779. [PMID: 30671023 DOI: 10.3389/fendo.2018.00779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
39 Chen Y, Hao J, Ma W, Tang Y, Gao C, Hao X. Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. J Gastrointest Surg. 2011;15:1026-1034. [PMID: 21484493 DOI: 10.1007/s11605-011-1493-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
40 Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol 2007;34:303-10. [PMID: 17674958 DOI: 10.1053/j.seminoncol.2007.05.003] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis]
41 Kassauei K, Habbe N, Mullendore ME, Karikari CA, Maitra A, Feldmann G. Mitochondrial DNA mutations in pancreatic cancer. Int J Gastrointest Cancer 2006;37:57-64. [PMID: 17827523 DOI: 10.1007/s12029-007-0008-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
42 Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-188. [PMID: 18039136 DOI: 10.1146/annurev.pathmechdis.3.121806.154305] [Cited by in Crossref: 489] [Cited by in F6Publishing: 433] [Article Influence: 37.6] [Reference Citation Analysis]